Figure 3
From: Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib
Overall survival (OS) and event-free survival (EFS) for the entire study population.
Figure 3 | Blood Cancer Journal
From: Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib
Overall survival (OS) and event-free survival (EFS) for the entire study population.
